ONC
NASDAQBeOne Medicines Ltd.
$299.83-12.50 (-4.00%)
News25/Ratings6
News · 26 weeks47-37%
2025-10-262026-04-19
Mix1990d
- Insider8(42%)
- Other4(21%)
- SEC Filings4(21%)
- Analyst2(11%)
- Earnings1(5%)
Latest news
25 items- PRBeOne Medicines to Announce First Quarter 2026 Financial Results on May 6BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncol
- SECAmendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.SCHEDULE 13D/A - BeOne Medicines Ltd. (0001651308) (Subject)
- SECSEC Form PRE 14A filed by BeOne Medicines Ltd.PRE 14A - BeOne Medicines Ltd. (0001651308) (Filer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- INSIDERSEC Form 4 filed by Lee Chan Henry4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- ANALYSTWolfe Research initiated coverage on BeOne Medicines with a new price targetWolfe Research initiated coverage of BeOne Medicines with a rating of Outperform and set a new price target of $340.00
- ANALYSTBeOne Medicines downgraded by Jefferies with a new price targetJefferies downgraded BeOne Medicines from Buy to Hold and set a new price target of $290.00
- INSIDERSVP, General Counsel Lee Chan Henry sold $102,300 worth of American Depositary Shares (341 units at $300.00) and exercised 341 units of American Depositary Shares at a strike of $191.64 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John was granted 444,912 units of Ordinary Shares, increasing direct ownership by 9% to 5,609,275 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai was granted 167,635 units of Ordinary Shares, increasing direct ownership by 12% to 1,619,059 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident and COO Wu Xiaobin was granted 247,546 units of Ordinary Shares, increasing direct ownership by 26% to 1,216,524 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Financial Officer Rosenberg Aaron was granted 119,587 units of Ordinary Shares, increasing direct ownership by 56% to 334,919 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry was granted 95,264 units of Ordinary Shares, increasing direct ownership by 43% to 318,370 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 10-K filed by BeOne Medicines Ltd.10-K - BeOne Medicines Ltd. (0001651308) (Filer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- PRBeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology LeadershipTotal global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announ
- PRBeOne Medicines to Present at Upcoming Investor ConferencesBeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. Archived replays will b
- PRBeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicine
- INSIDERSVP, General Counsel Lee Chan Henry sold $580,197 worth of American Depositary Shares (1,660 units at $349.52) and exercised 1,660 units of American Depositary Shares at a strike of $191.40 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare ConferenceCompany outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company's transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton's tyrosine kinase (BTK) inhibitors, as well as foundat
- INSIDERSVP, General Counsel Lee Chan Henry exercised 664 units of American Depositary Shares at a strike of $191.56 and sold $220,289 worth of American Depositary Shares (664 units at $331.76) (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEACombination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+)
- INSIDERPresident, Global Head of R&D Wang Lai was granted 427,895 units of Ordinary Shares, increasing direct ownership by 42% to 1,451,424 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patient
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - BeOne Medicines Ltd. (0001651308) (Filer)